Zhu H - Search Results

1

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities.

Ren A, Tong X, Xu N, Zhang T, Zhou F, Zhu H. Ren A, et al. Among authors: zhu h. Vaccines (Basel). 2023 Jan 12;11(1):165. doi: 10.3390/vaccines11010165. Vaccines (Basel). 2023. PMID: 36680011 Free PMC article. Review.

2

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.

Shi J, Zhang Z, Cen H, Wu H, Zhang S, Liu J, Leng Y, Ren A, Liu X, Zhang Z, Tong X, Liang J, Li Z, Zhou F, Huang L, Qin Y, Yang K, Zhang T, Zhu H. Shi J, et al. Among authors: zhu h. J Hematol Oncol. 2021 Oct 9;14(1):162. doi: 10.1186/s13045-021-01178-z. J Hematol Oncol. 2021. PMID: 34627328 Free PMC article.

3

Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.

Tang Q, Gu L, Zhou B, Shi J, Wu H, Zhu H, Xu Y, Zhang T. Tang Q, et al. Among authors: zhu h. Biopreserv Biobank. 2022 Dec;20(6):567-574. doi: 10.1089/bio.2021.0069. Epub 2022 Mar 16. Biopreserv Biobank. 2022. PMID: 35294840

4

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.

Wei J, Xiao M, Mao Z, Wang N, Cao Y, Xiao Y, Meng F, Sun W, Wang Y, Yang X, Chen L, Zhang Y, Zhu H, Zhang S, Zhang T, Zhou J, Huang L. Wei J, et al. Among authors: zhu h. Signal Transduct Target Ther. 2022 Apr 11;7(1):101. doi: 10.1038/s41392-022-00924-0. Signal Transduct Target Ther. 2022. PMID: 35399106 Free PMC article.

5

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Zhang S, Gu C, Huang L, Wu H, Shi J, Zhang Z, Zhou Y, Zhou J, Gao Y, Liu J, Leng Y, Liu X, Zhang Q, Huang L, Tong X, Young KH, Li J, Zhu H, Zhang T. Zhang S, et al. Among authors: zhu h. Sci Rep. 2022 Jun 21;12(1):10488. doi: 10.1038/s41598-022-14523-0. Sci Rep. 2022. PMID: 35729339 Free PMC article.

6

Dynamic Expression of EpCAM in Primary and Metastatic Lung Cancer Is Controlled by Both Genetic and Epigenetic Mechanisms.

Cui Y, Li J, Liu X, Gu L, Lyu M, Zhou J, Zhang X, Liu Y, Zhu H, Zhang T, Sun F. Cui Y, et al. Among authors: zhu h. Cancers (Basel). 2022 Aug 25;14(17):4121. doi: 10.3390/cancers14174121. Cancers (Basel). 2022. PMID: 36077658 Free PMC article.

7

B cell deficiency promotes the initiation and progression of lung cancer.

Wu H, Chen C, Gu L, Li J, Yue Y, Lyu M, Cui Y, Zhang X, Liu Y, Zhu H, Liao X, Zhang T, Sun F, Hu W. Wu H, et al. Among authors: zhu h. Front Oncol. 2022 Sep 29;12:1006477. doi: 10.3389/fonc.2022.1006477. eCollection 2022. Front Oncol. 2022. PMID: 36249034 Free PMC article.

8

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30⁺ lymphoma.

Zhang P, Yang X, Cao Y, Wang J, Zhou M, Chen L, Wei J, Mao Z, Wang D, Xiao Y, Zhu H, Zhang S, Zhang T, Zhang Y, Zhou J, Huang L. Zhang P, et al. Among authors: zhu h. Exp Hematol Oncol. 2022 Oct 17;11(1):72. doi: 10.1186/s40164-022-00323-9. Exp Hematol Oncol. 2022. PMID: 36253833 Free PMC article.

9

T-ALL Cells as Tool Cells for CAR T Therapy.

Ren A, Zhao Y, Zhu H. Ren A, et al. Among authors: zhu h. Vaccines (Basel). 2023 Apr 17;11(4):854. doi: 10.3390/vaccines11040854. Vaccines (Basel). 2023. PMID: 37112766 Free PMC article.

10

Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8⁺ T cells in the tumor microenvironment.

Cheng J, Yan J, Liu Y, Shi J, Wang H, Zhou H, Zhou Y, Zhang T, Zhao L, Meng X, Gong H, Zhang X, Zhu H, Jiang P. Cheng J, et al. Among authors: zhu h. Cell Metab. 2023 Jun 6;35(6):961-978.e10. doi: 10.1016/j.cmet.2023.04.017. Epub 2023 May 12. Cell Metab. 2023. PMID: 37178684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28,049 results

Search Page